Nearly 66% of all pharmaceutical launches don’t meet pre-launch sales expectations, according to a study conducted by McKinsey & Company. For the ones that do, only 53% continue to exceed forecasts by the third year. In a marketplace where the Food and Drug Administration (FDA) has approved 108 new drugs in the past three years, each launch should be optimized for success to take advantage of the current market opportunity.
